Clinical outcomes with oral cephalosporins as definitive treatment of Enterobacterales bacteremia from a urinary source based on cefazolin minimum inhibitory concentration

Cefazolin breakpoints differ for the treatment of Enterobacterales urinary tract infections and systemic infections. A retrospective, exploratory cohort study of 148 patients found no difference in 30-day treatment outcomes based on the blood culture cefazolin minimum inhibitory concentration (≤2 mcg/mL versus 4-16 mcg/mL) for patients transitioned to PO cephalosporins for the treatment of <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, or <i>Proteus mirabilis</i> bacteremia secondary to a urinary source. Further research should confirm these findings. .